- Home
- RPRX vs ROIV Comparison
RPRX vs ROIV Comparison
Compare RPRX & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RPRX | ROIV |
|---|---|---|
| Founded | 1996 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.0B | 21.0B |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | RPRX | ROIV |
|---|---|---|
| Price | $54.87 | $30.04 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 9 |
| Target Price | ★ $51.40 | $28.94 |
| AVG Volume (30 Days) | 3.3M | ★ 5.9M |
| Earning Date | 05-06-2026 | 05-28-2026 |
| Dividend Yield | ★ 1.90% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.67 | N/A |
| Revenue | ★ $2,378,193,000.00 | $8,260,000.00 |
| Revenue This Year | $38.63 | N/A |
| Revenue Next Year | $4.73 | $744.61 |
| P/E Ratio | $82.49 | ★ N/A |
| Revenue Growth | ★ 5.06 | N/A |
| 52 Week Low | $34.39 | $10.71 |
| 52 Week High | $56.50 | $32.79 |
Technical Indicators
Market Signals| Indicator | RPRX | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 58.10 | 56.52 |
| Support Level | $35.35 | $27.44 |
| Resistance Level | N/A | $32.79 |
| Average True Range (ATR) | 1.31 | 0.87 |
| MACD | -0.15 | 0.01 |
| Stochastic Oscillator | 50.00 | 86.99 |
Price Performance
Historical ComparisonAbout RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.